Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FAPI PET/CT Imaging in Non-Small Cell Lung Cancer
2025-523965-97-00Phase 2Authorised
- Sponsor
- Turku University Hospital
- Start
- Dec 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of [18F]-FAPI-74 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Turku University Hospital. Primary endpoint: SUV metrics of lesions. Planned start Dec 2025; status: authorised.
02
Drugs
[18F]-FAPI-74
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523965-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523965-97-00.